Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19

Given the speed of viral infection spread, repurposing of existing drugs has been given the highest priority in combating the ongoing COVID-19 pandemic. Only drugs that are already registered or close to registration, and therefore have passed lengthy safety assessments, have a chance to be tested i...

Descripción completa

Detalles Bibliográficos
Autores principales: Norinder, Ulf, Tuck, Astrud, Norgren, Kalle, Munic Kos, Vesna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Masson SAS. 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392152/
https://www.ncbi.nlm.nih.gov/pubmed/32763818
http://dx.doi.org/10.1016/j.biopha.2020.110582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392152/
https://www.ncbi.nlm.nih.gov/pubmed/32763818
http://dx.doi.org/10.1016/j.biopha.2020.110582

Ejemplares similares